111 related articles for article (PubMed ID: 1455361)
1. [The use of Capoten in systemic scleroderma].
Guseva NG; Anikina NV; Shcherbakov AB
Ter Arkh; 1992; 64(5):100-2. PubMed ID: 1455361
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Raynaud's phenomenon with captopril.
Tosi S; Marchesoni A; Messina K; Bellintani C; Sironi G; Faravelli C
Drugs Exp Clin Res; 1987; 13(1):37-42. PubMed ID: 3297593
[TBL] [Abstract][Full Text] [Related]
3. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.
Surwit RS; Gilgor RS; Allen LM; Duvic M
Arch Dermatol; 1984 Mar; 120(3):329-31. PubMed ID: 6367665
[TBL] [Abstract][Full Text] [Related]
4. [Raynaud's disease treated with captopril (Capoten). A randomized double-blind cross-over study].
Madsen JL; Hvidt S
Ugeskr Laeger; 1984 Sep; 146(36):2695-7. PubMed ID: 6393495
[No Abstract] [Full Text] [Related]
5. Captopril in the treatment of scleroderma renal crisis.
Thurm RH; Alexander JC
Arch Intern Med; 1984 Apr; 144(4):733-5. PubMed ID: 6370160
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of renal crisis in progressive systemic sclerosis with captopril].
Latorre LC; Mion D; Zerbini CA; Pastor EH; Resende C; Fidelis TS; Gabriel Júnior A; Assad RL; Cossermelli W
Rev Hosp Clin Fac Med Sao Paulo; 1985; 40(1):18-21. PubMed ID: 3903950
[No Abstract] [Full Text] [Related]
7. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
[TBL] [Abstract][Full Text] [Related]
8. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
[TBL] [Abstract][Full Text] [Related]
9. [Corinfar in the treatment of Raynaud's syndrome in systemic scleroderma (preliminary results)].
Shcherbakov AB; Guseva NG; Mach ES
Ter Arkh; 1985; 57(5):141-4. PubMed ID: 4023933
[TBL] [Abstract][Full Text] [Related]
10. Failure of captopril to reverse the renal crisis of scleroderma.
Brown EA; Macgregor GA; Maini RN
Ann Rheum Dis; 1983 Feb; 42(1):52-3. PubMed ID: 6338841
[TBL] [Abstract][Full Text] [Related]
11. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
[TBL] [Abstract][Full Text] [Related]
12. The peripheral vascular effects of nifedipine in Raynaud's syndrome associated with scleroderma: a double blind crossover study.
Finch MB; Dawson J; Johnston GD
Clin Rheumatol; 1986 Dec; 5(4):493-8. PubMed ID: 3816096
[TBL] [Abstract][Full Text] [Related]
13. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
Lukác J; Rovenský J; Tauchmannová H; Zitnan D
Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
[TBL] [Abstract][Full Text] [Related]
14. Raynaud's phenomenon and scleroderma.
Harper FE; LeRoy EC
Compr Ther; 1981 Feb; 7(2):45-51. PubMed ID: 6163587
[No Abstract] [Full Text] [Related]
15. [Intra-arterial reserpine in Raynaud's disease and syndrome].
Arcas Meca R; Ono Okabe S; Barroso-Moguel R; Quijano Pitman F
Arch Inst Cardiol Mex; 1972; 42(2):260-8. PubMed ID: 5028993
[No Abstract] [Full Text] [Related]
16. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
Colakoğlu M; Cobankara V; Akpolat T
Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial.
Shenoy PD; Kumar S; Jha LK; Choudhary SK; Singh U; Misra R; Agarwal V
Rheumatology (Oxford); 2010 Dec; 49(12):2420-8. PubMed ID: 20837499
[TBL] [Abstract][Full Text] [Related]
18. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
Fries R; Shariat K; von Wilmowsky H; Böhm M
Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
[TBL] [Abstract][Full Text] [Related]
19. Treatment of refractory ischemic skin ulcers in patients with Raynaud's phenomenon with PGE1 infusions.
Langevitz P; Buskila D; Lee P; Urowitz MB
J Rheumatol; 1989 Nov; 16(11):1433-5. PubMed ID: 2600942
[TBL] [Abstract][Full Text] [Related]
20. [Recuperation of the renal function with early use of captopril in sclerodermal renal crisis].
Lizasoain M; Martínez R; Fernández R; García-Díaz JD; Bello I; Praga M
Med Clin (Barc); 1988 Nov; 91(15):586-8. PubMed ID: 3067015
[No Abstract] [Full Text] [Related]
[Next] [New Search]
